Cover image of show PCR Perspectives

PCR Perspectives

Podcast by PCR

English

Technology & science

Limited Offer

2 months for 19 kr.

Then 99 kr. / monthCancel anytime.

  • 20 hours of audiobooks / month
  • Podcasts only on Podimo
  • All free podcasts
Get Started

About PCR Perspectives

Stay at the forefront of interventions for valvular heart disease, coronary, and structural interventions with expert insights and perspectives. These interviews explore the techniques, tools, and key topics shaping the ever-evolving field of interventional cardiology Hosted on Acast. See acast.com/privacy for more information.

All episodes

53 episodes

episode Long-term mortality following PCI with DES vs. CABG for left main disease artwork

Long-term mortality following PCI with DES vs. CABG for left main disease

Major LBT from EuroPCR 2026 This major late-breaking trial from #EuroPCR 2026 presents a landmark patient-level meta-analysis comparing PCI with drug-eluting stents (DES) versus CABG for left main coronary artery disease. Combining long-term data from the EXCEL, NOBLE, PRECOMBAT, and SYNTAX trials, the analysis found remarkably similar mortality outcomes between the two strategies at both 5 and 10 years. David Hildick-Smith and Brian Bergmark discuss how these findings challenge traditional assumptions about the long-term survival advantage of surgery and what they mean for heart team decision-making. ---------------------------------------- Hosted on Acast. See acast.com/privacy [https://acast.com/privacy] for more information.

21 May 2026 - 7 min
episode Coronary revascularisation in TAVI: meta-analysis of 4 Trials artwork

Coronary revascularisation in TAVI: meta-analysis of 4 Trials

Major LBTs from EuroPCR 2026 How should coronary artery disease (CAD) be managed in patients undergoing TAVI? At #europcr 2026, Martin Leon and Roberto Scarsini discuss the findings of a patient-level meta-analysis pooling data from four randomised trials: ACTIVATION, NOTION-3, FAITAVI, and TCW. The analysis included 1,050 patients with severe aortic stenosis and concomitant CAD, comparing medical therapy, angiography-guided PCI, and FFR-guided PCI strategies. At 1 year, PCI was associated with a lower rate of MACE compared with conservative management. Among the different strategies, FFR-guided PCI showed the greatest benefit, reinforcing the value of physiological assessment when treating these complex patients. Beyond the trial results, the conversation moves toward a practical algorithm for approaching severe AS and CAD, and raises important questions about when, how, and in whom revascularisation should really be performed. Listen to the full discussion to learn more about the implications of these findings for clinical practice. ---------------------------------------- Hosted on Acast. See acast.com/privacy [https://acast.com/privacy] for more information.

21 May 2026 - 9 min
episode LAA closure vs. NOAC in patients with atrial fibrillation across age groups in the CHAMPION AF study artwork

LAA closure vs. NOAC in patients with atrial fibrillation across age groups in the CHAMPION AF study

This major late-breaking trial from #EuroPCR 2026 highlights new insights from the CHAMPION AF study, one of the largest randomised trials comparing left atrial appendage closure (LAAC) with direct oral anticoagulants (DOACs) in patients with atrial fibrillation. In this interview, Philippe Garot and Jens Erik Nielsen-Kudsk discuss the pre-specified age subgroup analysis, showing consistent efficacy across younger and older populations, with significantly lower bleeding rates in the LAAC arm and very high procedural safety. They also explore how these findings could influence future patient selection and expand the role of LAAC in stroke prevention strategies for AF patients. ---------------------------------------- Hosted on Acast. See acast.com/privacy [https://acast.com/privacy] for more information.

21 May 2026 - 9 min
episode What does ORBITA CTO tell us about CTO PCI? artwork

What does ORBITA CTO tell us about CTO PCI?

Chronic total occlusions (CTOs) remain a key area of uncertainty in interventional cardiology, particularly regarding symptom improvement after PCI. In this EuroPCR 2026 interview, John Davies and Sarosh Khan discuss the ORBITA CTO trial and its implications for clinical practice. As the first double-blind, placebo-controlled randomised trial in CTO PCI, ORBITA CTO evaluates whether symptom relief, especially angina frequency, truly exceeds placebo in carefully selected patients. The discussion highlights the study’s design, key findings, and what they mean for CTO operators and clinicians managing patients with CTOs in everyday practice. ---------------------------------------- Hosted on Acast. See acast.com/privacy [https://acast.com/privacy] for more information.

20 May 2026 - 7 min
En fantastisk app med et enormt stort udvalg af spændende podcasts. Podimo formår virkelig at lave godt indhold, der takler de lidt mere svære emner. At der så også er lydbøger oveni til en billig pris, gør at det er blevet min favorit app.
En fantastisk app med et enormt stort udvalg af spændende podcasts. Podimo formår virkelig at lave godt indhold, der takler de lidt mere svære emner. At der så også er lydbøger oveni til en billig pris, gør at det er blevet min favorit app.
Rigtig god tjeneste med gode eksklusive podcasts og derudover et kæmpe udvalg af podcasts og lydbøger. Kan varmt anbefales, om ikke andet så udelukkende pga Dårligdommerne, Klovn podcast, Hakkedrengene og Han duo 😁 👍
Podimo er blevet uundværlig! Til lange bilture, hverdagen, rengøringen og i det hele taget, når man trænger til lidt adspredelse.

Choose your subscription

Most popular

Limited Offer

Premium

20 hours of audiobooks

  • Podcasts only on Podimo

  • No ads in Podimo shows

  • Cancel anytime

2 months for 19 kr.
Then 99 kr. / month

Get Started

Premium Plus

Unlimited audiobooks

  • Podcasts only on Podimo

  • No ads in Podimo shows

  • Cancel anytime

Start 7 days free trial
Then 129 kr. / month

Start for free

Only on Podimo

Popular audiobooks

Get Started

2 months for 19 kr. Then 99 kr. / month. Cancel anytime.